Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Clinical Updates and Expert Guidance in Prostate Cancer

Access Activity

Overview / Abstract:


Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 31,620 deaths annually. Median overall survival remains less than 2 years.


Medical oncologists, radiation oncologists, urologists, and other health care professionals involved in the treatment of patients with prostate cancer.


Upon completion of this activity, participants should be able to:

1.) Evaluate recent efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant nonmetastatic prostate cancer
2.) Evaluate emerging efficacy and safety data on novel therapeutic strategies for patients with castration-sensitive/resistant metastatic prostate cancer
3.) Assess recent study findings on novel combination and sequential treatment strategies for prostate cancer and their implications for current practice


Jun 02, 2021


Nurse Practitioner , Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

1.25 CME, 1.25 MOC



Presenters / Authors / Faculty

Judd W. Moul, MD (Chairperson)
Professor of Urologic Surgery
Duke University School of Medicine

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Urology

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Sanofi.

Keywords / Search Terms

i3 Health i3 Health, prostate cancer, castration-resistant prostate cancer, CRPC, CME, free CE CME, free CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map